Media OutReach
AilsynBio and Dong-E-E-Jiao Sign Project Cooperation Agreement Empowering Traditional Medicine with AI to Open a New Chapter in the Health Industry
The ceremony brought together influential leaders and experts from industry, academia, and research sectors, including senior representatives from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation (HKSTP), and The University of Hong Kong (HKU), to witness this significant milestone.
Dr. Bo Chen, Chief Scientific Officer of China Resources Pharmaceutical, noted:
“This collaboration with Dong-E-E-Jiao and AilsynBio is a key initiative for China Resources Pharmaceutical in advancing the modernization of Traditional Chinese Medicine (TCM). It represents a deep integration of industry, academia, and research in the field of ‘AI + TCM’ between Mainland China and Hong Kong. We look forward to leveraging scientific research and industrial resources from both regions to overcome the challenges of TCM’s mechanisms of action and to pave an innovative path for TCM to evolve from empirical medicine to evidence-based medicine.”
Mr. Liang Zheng, Vice President of Dong-E-E-Jiao, stated:
“As a core strategic product for Dong-E-E-Jiao, deepening the scientific value of Compound E-Jiao Syrup is crucial for our brand upgrade. This cooperation will strengthen the scientific foundation of our products in the field of women’s health, helping Dong-E-E-Jiao accelerate into a new stage of ‘reshaping TCM wisdom through technological innovation.'”
Mr. Pierre Wang, Managing Director of HKU Versitech Limited, stated:
“HKU Versitech is honored to witness this project cooperation between HKU spin-off AilsynBio Ltd. and China Resources Pharmaceutical subsidiary Dong-E E-Jiao, a partnership that exemplifies the successful translation of Hong Kong’s top-tier academic research into high-impact industrial applications. This cooperation will continue to serve as a vital catalyst for the company’s rapid international growth and its mission to scale cutting-edge biotechnology globally.”
Looking ahead, the two parties will focus on three key collaborative directions:
- Advancing AI-driven innovation: Leveraging AilsynBio’s AI drug discovery platform to accelerate biopharmaceutical R&D processes.
- Launching specialized research: Engaging in in-depth cooperation on the “Premature Ovarian Insufficiency (POI)” research project.
- Promoting cross-border fusion: Exploring the integration of biotechnology, AI, and traditional medicine to jointly create a new paradigm for the health industry.
During the ceremony, AilsynBio and Dong-E-E-Jiao signed the agreement on behalf of their respective organizations. The signing was witnessed by Dr. Bo Chen, Chief Scientist of China Resources Pharmaceutical; Mr. Eric Or, Chief Ecosystem Development Officer of HKSTP; and Mr. Pierre Wang, Managing Director of HKU Versitech.
AilsynBio stated that this cooperation is not only a combination of cutting-edge technology and traditional medicine, but also a strategic layout for future healthcare innovation. By leveraging AI technology, the partnership aims to inject technological vitality into traditional medicine for the benefit of more patients.
Hashtag: #AilsynBio #昂心生物
The issuer is solely responsible for the content of this announcement.
About China Resources Pharmaceutical
China Resources Pharmaceutical Group Limited (Stock code: 03320.HK) stands as a premier, integrated pharmaceutical enterprise in China. Our comprehensive operations span the entire value chain, from R&D and manufacturing to distribution and retail. We host a robust portfolio of listed subsidiaries and maintain advanced innovation platforms dedicated to both chemical and biological pharmaceuticals. Our diverse products including chemical drugs, Traditional Chinese Medicine (TCM), biologics, health supplements, and medical devices, addressing a vast spectrum of therapeutic areas. We are the proud custodian of iconic brands such as “999”, “Dong-E-E-Jiao”, and “Jiangzhong”. Guided by our mission to “Safeguard Human Health and Enhance Quality of Life,” we are dedicated to evolving into a trusted, innovation-driven leader in pharmaceutical and healthcare sector.
About Dong-E E-Jiao
Dong-E E-Jiao Co., Ltd. (000423.SZ) is an enterprise engaged in the production and operation of E-Jiao and related products. As a subsidiary of state-owned China Resources Group, it is primarily involved in the R&D, production, and sales of E-Jiao and related Chinese patent medicines, health foods, and food products. The company, formerly known as Shandong Dong-E E-Jiao Factory, was established in 1952, listed on the Shenzhen Stock Exchange in 1996, and joined China Resources Group in 2005. The company houses the National Gelatin Traditional Chinese Medicine Engineering Technology Research Center and a postdoctoral research workstation. It is recognized as a National High-Tech Enterprise, a National Innovative Enterprise, a National Intangible Cultural Heritage Heritage Enterprise, and a National Traditional Chinese Medicine Culture Publicity and Education Base. Its products are sold not only in the domestic market but also in over 10 countries and regions, including Southeast Asia, Europe, and the Americas.
About AilsynBio
AilsynBio is an AI-native biotechnology company dedicated to the rational design of differentiated therapeutics. By combining artificial intelligence, physics-based modeling, and deep medicinal chemistry expertise, the company delivers end-to-end drug discovery solutions spanning novel target identification, mechanism-of-action elucidation, and lead design and optimization. Validated through collaborations with multiple top-tier pharmaceutical companies, AilsynBio’s technology offers industry-leading predictive accuracy and enables the delivery of IND-ready candidate molecules with greater efficiency, higher success rates, and a fraction of the time and cost required by conventional approaches.
Media OutReach
Owner-Operated Serviced Office CoWorkSpace Opens at 6 Raffles Quay Level 16, Offering Members Stable Pricing in a Landlords’ Market
As Singapore CBD office rents rise for a fifth consecutive quarter and vacancy hits a record low, CoWorkSpace aims to shield members from rent increases that flex operators typically pass through.
SINGAPORE – Media OutReach Newswire – 26 May 2026 – CoWorkSpace is conveniently located at 6 Raffles Quay #16-01, occupying an entire floor within the office tower and comprising more than 50 private suites designed for startups, SMEs, and established corporations across shipping, financial intermediaries, family offices, professional services, business consultancy, technology, and trade-related industries.
Hashtag: #ServicedOffice #Coworking #CoworkingSpace #RafflesQuay #RafflesPlace #SingaporeCBD #SGCBD #PrivateOffice #PrivateSuites #OwnerOperated #FlexibleWorkspace #BusinessAddress #SMESingapore #SGBusiness #CoWorkSpace
https://www.coworkspace.com.sg/
CoWorkSpace Serviced Office.
Media OutReach
JOYY Reports First Quarter 2026 Financial Results: Total Revenue YoY Growth Hits Multi-Year High
In the first quarter, JOYY’s total revenues reached US$555.7 million, up 12.4% year over year, representing the Company’s highest year-over-year growth rate in recent years. Social entertainment revenue increased 3.2% year over year to US$400.4 million. BIGO Ads ad tech and SHOPLINE e-commerce, the second growth engine of the Company, maintained strong growth momentum. BIGO Ads revenue reached US$124.8 million, up 55.6% year over year, while SHOPLINE contributed US$30.5 million, up 16.1% year over year.
In the first quarter, the Company’s non-GAAP1 operating income increased 22.5% year over year to US$38.0 million, while non-GAAP1 EBITDA grew 13.2% year over year to US$45.7 million. Operating cash inflow for the quarter was US$46.0 million. Net cash as of March 31, 2026 stood at US$3.18 billion.
Simultaneously, JOYY announced a new share repurchase program, under which the Company is authorized to repurchase up to US$600 million of its shares until the end of 2028, and a new quarterly dividend program, under which a total of approximately US$900 million in cash will be distributed on a quarterly basis between 2026 and 2028. The new shareholder return program amounts to approximately US$1.5 billion, underscoring JOYY’s confidence in its long-term growth potential.
- This press release includes certain non-GAAP financial measures as additional clarifying items to aid investors in further understanding the Company’s performance and the impact that these items and events had on the financial results. The non-GAAP financial measures provided above should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with GAAP. For details of the non-GAAP measures, including the reconciliations of GAAP measures to non-GAAP measures, please refer to the press release titled “JOYY Reports First Quarter 2026 Unaudited Financial Results” issued by the Company on May 26, 2026.
Hashtag: #JOYY
The issuer is solely responsible for the content of this announcement.
Media OutReach
“Made in Binzhou” Heads to Tianzhou-10 Cargo Spacecraft——Binzhou Sci-Tech Power Embarks on a Hardcore Space Mission
This initiative is a collaborative effort involving the University of Chinese Academy of Sciences (UCAS), the National Space Science Center of the Chinese Academy of Sciences, and the Binzhou Weiqiao UCAS High Technology Research Institute. The successful launch marks a historic “zero-to-one” breakthrough, representing the first time private sci-tech forces from Binzhou and indeed Shandong province have reached space. It also stands as China’s first in-space experiment to study the solidification of lightweight high-entropy alloys under the dual-field coupling of “microgravity and rotating magnetic fields.”
As a national-level “space laboratory,” the manned space station hosts world-class research facilities and serves as a core platform for disruptive innovation in new materials. This successful deployment not only highlights the institute’s cutting-edge research capabilities but also signifies a deep integration between corporate scientific research and national aerospace engineering. Looking ahead, the institute will continue its deep dive into frontier fields such as space materials and lightweight alloys. By strengthening collaborative innovation across industry, academia, and research, they aim to empower the upgrading of the new materials industry with technological innovation, contributing both wisdom and strength to the development of China’s manned space program and the cultivation of new quality productive forces.
Hashtag: #BinzhouInformationOffice
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn